K.A.O. Ellem

3.6k total citations
97 papers, 2.9k citations indexed

About

K.A.O. Ellem is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, K.A.O. Ellem has authored 97 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Molecular Biology, 34 papers in Oncology and 21 papers in Immunology. Recurrent topics in K.A.O. Ellem's work include Virus-based gene therapy research (13 papers), Immunotherapy and Immune Responses (13 papers) and DNA Repair Mechanisms (10 papers). K.A.O. Ellem is often cited by papers focused on Virus-based gene therapy research (13 papers), Immunotherapy and Immune Responses (13 papers) and DNA Repair Mechanisms (10 papers). K.A.O. Ellem collaborates with scholars based in Australia, United States and China. K.A.O. Ellem's co-authors include John S. Colter, Brian Gabrielli, Colin P. C. De Souza, Ryanne A. Brown, Nicholas K. Hayward, Wei Ming, Christopher Schmidt, Ralph B. L. Gwatkin, Graham F. Kay and S L Rhode and has published in prestigious journals such as Nature, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

K.A.O. Ellem

97 papers receiving 2.8k citations

Peers

Countries citing papers authored by K.A.O. Ellem

Since Specialization

Citations

This map shows the geographic impact of K.A.O. Ellem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K.A.O. Ellem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K.A.O. Ellem more than expected).

Fields of papers citing papers by K.A.O. Ellem

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K.A.O. Ellem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K.A.O. Ellem. The network helps show where K.A.O. Ellem may publish in the future.

Co-authorship network of co-authors of K.A.O. Ellem

This figure shows the co-authorship network connecting the top 25 collaborators of K.A.O. Ellem. A scholar is included among the top collaborators of K.A.O. Ellem based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K.A.O. Ellem. K.A.O. Ellem is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Survival outcomes for men with castrate-resistant prostate cancer (CRPC) treated with a dendritic-cell based vaccine in a randomized controlled trial 2014 ·Queensland's institutional digital repository (The University of Queensland) ·Robert A. Gardiner, Peter MacTaggart, John Yaxley, Dianne Nicol, Shawn M. McClintock, K.A.O. Ellem, David Hart, G. J. Seymour, (unknown), Charles W. Schmidt	3
2	An extraordinarily high level of IL-15 expression by a cell line transduced with a modified BMGneo vector displays hypoxic upregulation 2006 ·Molecular Biotechnology ·(unknown), Michael Hamilton, (unknown), Christopher Schmidt, K.A.O. Ellem	4
3	Search for "weapons of mass destruction" for cancer -- immuno/ gene therapy comes of age. 2005 ·Publikationsdatenbank der Fraunhofer-Gesellschaft (Fraunhofer-Gesellschaft) ·Wei Ming, Pat Metharom, K.A.O. Ellem, Stefan Barth	3
4	The significance of controlled conditions in lentiviral vector titration and in the use of multiplicity of infection (MOI) for predicting gene transfer events 2004 ·Queensland's institutional digital repository (The University of Queensland) ·(unknown), Pat Metharom, (unknown), K.A.O. Ellem, G. J. Cleghorn, Malcolm West, Wei Ming	4
5	Microarray expression profiling in melanoma reveals a BRAF mutation signature 2004 ·Oncogene ·Sandra Pavey, Peter A. Johansson, Leisl Packer, Jennifer M. Taylor, Mitchell Stark, Pamela M. Pollock, Graeme J. Walker, Glen M. Boyle, Ursula L. Harper, Sarah‐Jane Cozzi, Katherine Hansen, Laura M. Yudt, Christopher Schmidt, Peter Hersey, K.A.O. Ellem, Michael G. E. OʼRourke, Peter G. Parsons, Paul Meltzer, Markus Ringnér, Nicholas K. Hayward	136
6	Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine 2003 ·Cancer Immunology Immunotherapy ·Michael G. E. OʼRourke, (unknown), Catherine Lanagan, (unknown), Jie Yang, JOHN R. BELL, (unknown), (unknown), (unknown), David M. Purdie, Suzanne Elliott, K.A.O. Ellem, Christopher Schmidt	146
7	Treatment of non‐resectable hepatocellular carcinoma with autologous tumor‐pulsed dendritic cells 2002 ·Journal of Gastroenterology and Hepatology ·Andrew Ladhams, Christopher Schmidt, Garwin Sing, (unknown), (unknown), (unknown), Russell W. Strong, Barbara Leggett, Lawrie W. Powell, Guy J. Maddern, K.A.O. Ellem, Graham Cooksley	57
8	Development of disabled, replication-defective gene transfer vectors from the Jembrana disease virus, a new infectious agent of cattle 2001 ·Veterinary Microbiology ·Pat Metharom, (unknown), Haibin Xia, K.A.O. Ellem, G.E. Wilcox, Wei Ming	12
9	Novel bovine lentiviral vectors based on Jembrana disease virus 2000 ·The Journal of Gene Medicine ·Pat Metharom, (unknown), (unknown), K.A.O. Ellem, John MacMillan, Ross W. Shepherd, G.E. Wilcox, Wei Ming	41
10	Centrosomal and Cytoplasmic Cdc2/Cyclin B1 Activation Precedes Nuclear Mitotic Events 2000 ·Experimental Cell Research ·Colin P. C. De Souza, K.A.O. Ellem, Brian Gabrielli	120
11	Multiple Splicing Variants of cdc25B Regulate G2/M Progression 1999 ·Biochemical and Biophysical Research Communications ·Alistair R. R. Forrest, (unknown), (unknown), (unknown), Ian D. Tonks, Nicholas K. Hayward, K.A.O. Ellem, Brian Gabrielli	51
12	UVC activation of the HeLa cell membrane “TGFαASE,” a metalloenzyme 1997 ·Journal of Cellular Biochemistry ·Terrence J. Piva, Darren Krause, K.A.O. Ellem	7
13	Ultraviolet light-induced G2 phase cell cycle checkpoint blocks cdc25-dependent progression into mitosis 1997 ·Oncogene ·Brian Gabrielli, (unknown), (unknown), K.A.O. Ellem	55
14	Hyperphosphorylation of the N-terminal Domain of Cdc25 Regulates Activity toward Cyclin B1/Cdc2 But Not Cyclin A/Cdk2 1997 ·Journal of Biological Chemistry ·Brian Gabrielli, (unknown), (unknown), K.A.O. Ellem	85
15	Loss and shedding of surface markers from the leukemic myeloid monocytic line THP-1 induced to undergo apoptosis 1996 ·Journal of Cellular Biochemistry ·(unknown), Ruth M. Kluck, K.A.O. Ellem	10
16	UV induction of transforming growth factor alpha in melanoma cell lines is a posttranslational event 1992 ·Journal of Cellular Physiology ·Georgia Chenevix‐Trench, M. P. Cullinan, K.A.O. Ellem, Nicholas K. Hayward	13
17	Detection of somatic mutations in tumours of diverse types by DNA fingerprinting with M13 phage DNA 1990 ·International Journal of Cancer ·Nicholas K. Hayward, Philip Chen, Derek J. Nancarrow, John H. Kearsley, Peter J. Smith, Chev Kidson, K.A.O. Ellem	9
18	TaqI polymorphism within the c-Ha-ras-1 VTR is associated with melanoma 1989 ·Human Genetics ·Nicholas K. Hayward, Derek J. Nancarrow, Peter G. Parsons, C Kidson, K.A.O. Ellem	4
19	A TaqI RFLP of the human TGFα gene is significantly associated with cutaneous malignant melanoma 1988 ·International Journal of Cancer ·Nicholas K. Hayward, Derek J. Nancarrow, K.A.O. Ellem, Peter G. Parsons, Chev Kidson	12
20	Subfractionation of CsCI-purified H-1 parvovirus on metrizamide gradients 1979 ·Virology ·(unknown), M. S. Hopkins, K.A.O. Ellem	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact